Phase 3 N=16 Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
Hypereosinophilic Syndrome
Primary: Number of Participants Who Experienced HES Flares Over the 52-Week Study Treatment Period — 10; 4; 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=338 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
Moderate Plaque Psoriasis
Primary: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 — 12.4; 74.2 Percentage of participants…
Phase 3 N=666 Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population — 5.55; 5.55 Months — p=0.502
Phase 3 N=13,553 A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
COVID-19
Primary: Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29 — 2340.9; 1753.8 AU/mL
Phase 3 N=3 Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency
Arginase 1 Deficiency
Primary: Change From Baseline in Plasma Arginine Concentrations in Subjects <24 Months of Age With Arginase 1 Deficiency (ARG1-D). — -221.53 μM
Phase 3 N=105 Evaluate the Neurological Effects of EryDex on Subjects With A-T
Ataxia Telangiectasia
Primary: Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS) — 0.94; 2.24 RmICARS score (0-29 points)
Phase 3 N=51 A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.18 Percentage-point of HbA1c
Phase 3 N=121 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Colitis, Ulcerative
Primary: Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score — 51.1; 43.5 percentage of participants
Phase 3 N=789 Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Non-small Cell Lung Cancer
Primary: Part 1: Overall Survival (OS) — 15.9; 20.1; 13.9 months — p=0.1782
Phase 3 N=119 An Exploratory Study of PQ Grass 27600 SU
Rhinitis, Allergic, Seasonal
Primary: CSMS (Combined Symptom and Medication Score) Averaged Over the Peak Grass Pollen Season (GPS) — 1.14; 1.03; 1.70; 1.42 score on a scale — p=0.0325
Phase 3 N=256 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Neuroendocrine Tumors · Advanced Cancer
Primary: Efficacy of Axitinib in Terms of PFS (Investigator Assessment) — 17.2; 13.1 months — p=0.324
Phase 3 N=1,049 A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA — 10.0; 4.0; 5.8; 5.4 Percentage of participants
Phase 3 N=100 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms
Influenza
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 24; 12; 2; 0 Participants
Phase 3 N=512 A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Obesity · Diabetes Mellitus, Type 2
Primary: Relative Change in Body Weight — -13.5; -10.7; -4.0 Percentage (%) change in body weight — p=<0.0001
Phase 3 N=959 Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Hepatocellular Carcinoma
Primary: Recurrence-Free Survival (RFS) — 46.7; 45.5 Months — p=0.7190